The Prognostic Significance of Serum Lactate Dehydrogenase-to-albumin Ratio in Colorectal Cancer
Overview
Authors
Affiliations
Purpose: The purpose of our study was initially to explore the prognostic role of LDH-to-albumin ratio in patients with colorectal carcinoma (CRC) undergoing curative resection.
Methods: The retrospective study included 295 CRC patients that underwent curative resection. According to time-dependent receiver operating characteristics (ROC) analysis, the optimal cutoff value for pretreatment LDH-to-albumin ratio was 52.7. Cox regression univariate and multivariate analyses were utilized to analyze the prognostic factors for disease-free survival (DFS) and overall survival (OS).
Results: The 295 participants included 117 women (39.7%) and had an overall mean age of 55.8 ± 14.1 years. The median follow-up period was 31.8 ± 21 months (range, 6-78 months) and 53 patients (18.0%) died from cancer during the follow-up period. The 5-year DFS and OS rates were 65.4% and 68.5% in patients with LDH-to-albumin ratio <52.7 (n = 152), and were 55.2% and 55.4% in patients with LDH-to-albumin ratio ≥52.7 (n = 143), respectively. Kaplan-Meier curves showed that LDH-to-albumin ratio ≥52.7 was significantly associated with worse DFS and OS (P = 0.003 and P < 0.001, respectively). Multivariate analyses revealed that LDH-to-albumin ratio was an independent predictor of resectable CRC (odds ratio, 2.104; 95% confidence interval, 1.112-3.982; P = 0.022).
Conclusion: Our study revealed that high pretreatment LDH-to-albumin ratio level was an unfavorable prognosticator in patients with CRC undergoing curative resection. LDH-to-albumin ratio is a candidate to be a prognostic biomarker in clinical practice.
Luo M, Wei H, Qiu M, Su C, Ning R, Zhou S Front Immunol. 2025; 16:1473962.
PMID: 40013138 PMC: 11861202. DOI: 10.3389/fimmu.2025.1473962.
Ekin A, Misirci S, Oztop H, Hacimustafaoglu A, Coskun B, Yagiz B Diagnostics (Basel). 2025; 14(24.
PMID: 39767141 PMC: 11674256. DOI: 10.3390/diagnostics14242780.
Wang X, Ji X J Inflamm Res. 2024; 17:5129-5138.
PMID: 39104906 PMC: 11298564. DOI: 10.2147/JIR.S472041.
Xia X, Tan S, Zeng R, Ouyang C, Huang X Open Med (Wars). 2024; 19(1):20240901.
PMID: 38584822 PMC: 10996934. DOI: 10.1515/med-2024-0901.
Xu W, Huo J, Hu Q, Xu J, Chen G, Mo J Clin Exp Nephrol. 2024; 28(9):882-893.
PMID: 38584195 DOI: 10.1007/s10157-024-02500-y.